Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 111
References
Ahonkhai, V. 2012. Regulatory issues affecting MDR-TB SLDs. Presentation at IOM work-
shop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs
for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC.
Atun, R. 2012. Challenges and barriers to efficient operation of existing supply chain. Presen-
tation at IOM workshop on Developing and Strengthening the Global Supply Chain for
Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington,
DC.
Cepheid. 2012. Cepheid announces first phase of Xpert MTB/RIF buy-down for high
burden developing countries. http://www.cepheid.com/company/news-events/press-
releases/?releaseID=698417 (accessed October 1, 2012).
Comstock, G. 2012. Learning from other models: PEPFAR’s supply chain management
system (SCMS). Presentation at IOM workshop on Developing and Strengthening the
Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July
31–August 1, Washington, DC.
Ditiu, L. 2012. GDF vision for SLD supply chain. Presentation at IOM workshop on Devel-
oping and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-
Resistant Tuberculosis, July 31–August 1, Washington, DC.
Fraser, H. S., J. Blaya, S. S. Choi, C. Bonilla, and D. Jazayeri. 2006. Evaluating the impact
and costs of deploying an electronic medical record system to support TB treatment in
Peru. AMIA Annual Symposium Proceedings 264-268.
Hedman, L. 2012. Quality of 2nd line medicines for tuberculosis. Presentation at IOM work-
shop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs
for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington, DC.
IOM (Institute of Medicine). 2009. Addressing the threat of drug-resistant tuberculosis: A
realistic assessment of the challenge: Workshop summary. Washington, DC: The National
Academies Press.
IOM. 2011a. The emerging threat of drug-resistant tuberculosis in Southern Africa: Global
and local challenges and solutions: Workshop summary. Washington, DC: The National
Academies Press.
111
OCR for page 112
112 GLOBAL SUPPLY CHAIN FOR SECOND-LINE DRUGS FOR MDR TB
IOM. 2011b. The new profile of drug-resistant tuberculosis in Russia: A global and local
perspective: Workshop summary. Washington, DC: The National Academies Press.
IOM. 2012. Facing the reality of drug-resistant tuberculosis in India: Challenges and potential
solutions: Workshop summary. Washington, DC: The National Academies Press.
Keshavjee, S. 2012. Background on the Green Light Committee and the second line tubercu-
losis drug supply chain. Presentation at IOM workshop on Developing and Strengthening
the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis,
July 31–August 1, Washington, DC.
Keshavjee, S., and P. Farmer. 2012. Tuberculosis, drug resistance, and the history of modern
medicine. New England Journal of Medicine 367(10):931-936.
Keshavjee, S., and K. Seung. 2008. Stemming the tide of multidrug-resistant tuberculo-
sis: Major barriers to addressing the growing epidemic. http://www.iom.edu/~/media/
Files/Activity%20Files/Research/DrugForum/IOM_MDRTB_whitepaper_2009_01_14_
FINAL_Edited.pdf (accessed September 15, 2011).
Kimerling, M. 2012. SLD Financing Issues: IOM workshop on the global supply chain for
second-line drugs for MDR-TB. Presentation at IOM workshop on Developing and
Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant
Tuberculosis, July 31–August 1, Washington, DC.
Mostaghim, S. 2012. MDR-TB drugs: Challenges and barriers to efficient operation of exist-
ing supply chain. Presentation at IOM workshop on Developing and Strengthening the
Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July
31–August 1, Washington, DC.
MSF (Médecins Sans Frontières) and IUATLD (International Union Against Tuberculosis and
Lung Disease). 2011. DR-TB drugs under the microscope: Sources and prices for drug-
resistant tuberculosis medicines. http://www.msfaccess.org/our-work/addressing-medical-
challenges/article/888 (accessed October 1, 2012).
MSH (Management Sciences for Health). 2011. Quality assurance for pharmaceuticals. http://
www.msh.org/resource-center/publications/upload/MDS3-Ch19-QualityAssurance-
Nov2011.pdf (accessed November 13, 2012).
Ripin, D. 2012. Lessons learned from catalyzing and sustaining access to pediatric HIV treat-
ments. Presentation at IOM workshop on Developing and Strengthening the Global Sup-
ply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August
1, Washington, DC.
Sims, T. 2012. Creating innovative solutions for MDR-TB: Ideas from the MDR-TB inno-
vation summit. Presentation at IOM workshop on Developing and Strengthening the
Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis, July
31–August 1, Washington, DC.
Wallengren, K., F. Scano, P. Nunn, B. Margot, S. Buthelezi, B. Williams, A. Pym, E. Y.
Samuel, F. Mirzayev, W. Nkhoma, L. Mvusi, and Y. Pillay. 2011. Drug-resistant tu-
berculosis, KwaZulu-Natal, South Africa, 2001-2007. Emerging Infectious Diseases
17(10):1913-1916.
Walsh, J. A., and K. S. Warren. 1979. Selective primary health care: An interim strategy for dis-
ease control in developing countries. New England Journal of Medicine 301(18):967-974.
WHO (World Health Organization). 2006. Guidelines for the programmatic management of
drug-resistant tuberculosis. http://whqlibdoc.who.int/publications/2006/9241546956_
eng.pdf (accessed October 1, 2012).
WHO. 2010. Global Tuberculosis Control: WHO report 2010. http://www.who.int/tb/
publications/global_report/2010/en/index.html (accessed September 18, 2011).
OCR for page 113
REFERENCES 113
Yadav, P. 2012. Supply chain for MDR-TB: Challenges and ideas for improvement. Presenta-
tion at IOM workshop on Developing and Strengthening the Global Supply Chain for
Second-Line Drugs for Multidrug-Resistant Tuberculosis, July 31–August 1, Washington,
DC.
Zhao, Y., S. Xu, L. Wang, D. P. Chin, S. Wang, G. Jiang, H. Xia, Y. Zhou, Q. Li, X. Ou,
Y. Pang, Y. Song, B. Zhao, H. Zhang, G. He, J. Guo, and Y. Wang. 2012. National
Survey of Drug-Resistant Tuberculosis in China. New England Journal of Medicine
366(23):2161-2170.
OCR for page 114
